For patients with HER2+ early breast cancer cT1a and b (i.e., ≤1 cm) without evidence of nodal disease (cN0), the standard of care is timely surgery followed by adjuvant treatment depending on the pathologic staging of disease (see Recommendations 3–5) (strong recommendation). Here, ERBB2 is linked to breast carcinoma.